Detailed information of GABPA

  1. Home
  2. TF > GABPA

Dataset summary

TF Name: GABPA Species: Homo sapiens
Cell-type/Tissue: MCF7 (Invasive ductal breast carcinoma) Condition/Source:
JASPAR ID: MA0062.3 Collections: Permissive
References: GEO GSE72082

External links

Models for profile: MA0062.3

Download TFBSs (hg38)

Download TFBSs in BED and FASTA format

Download trained model

Download trained prediction models

Visualize TFBSs in UCSC

Send TFBSs BED file to UCSC genome browser

Summary plots

Statistical details

Model Peak caller Model ID Enrichment Zone TFBSs Score threshold Centrality p-value (log10)
DAMO MACS MA0062.3 21.5 1251 83.8 NS

35 datasets found for the same TF (GABPA) in other cell-types/tissues

TF Name Cell-line Condition/Source Collections Species Identifiers JASPAR ID
GABPA A549 (lung carcinoma) 1 h with 0.02% Ethanol (Myers) Permissive Robust Homo sapiens ENCSR000BPY MA0062.3
GABPA CUTLL1 (T-cell lymphoblastic lymphoma 1) vehicle Permissive Robust Homo sapiens GSE51800 ... MA0062.3
GABPA bone marrow-derived macrophages No treatment Permissive Robust Mus musculus GSE88699 ... MA0062.3
GABPA bone marrow-derived macrophages No treatment Permissive Robust Mus musculus GSE88699 ... MA0062.3
GABPA bone marrow-derived macrophages alpha amanitin 10μg/ml for 5 hours (SIGMA) Permissive Robust Mus musculus GSE88699 ... MA0062.3
GABPA THP-1 (acute monocytic leukemia) Treatment: 100 nM ethanol for 24 hrs Permissive Robust Homo sapiens GSE98093 ... MA0062.3
GABPA THP-1 (acute monocytic leukemia) Treatment: 100 nM 1,25(OH)2D3 for 24 hrs Permissive Homo sapiens GSE98093 ... MA0062.3
GABPA EML -C1(EML, clone 1) Strain: B6D2F1 Genotype: CD34 negative Permissive Mus musculus GSE100689 ... MA0062.3
GABPA GM12878 (female B-cells lymphoblastoid cell line) Permissive Robust Homo sapiens ENCSR000BGC MA0062.3
GABPA HeLa S3 (cervical adenocarcinoma) Permissive Robust Homo sapiens ENCSR000BHS MA0062.3
GABPA WA01 (H1, human embryonic stem cells) Permissive Homo sapiens ENCSR000BIW MA0062.3
GABPA HepG2 (hepatoblastoma) Permissive Robust Homo sapiens ENCSR000BJK MA0062.3
GABPA K562 (myelogenous leukemia) Permissive Robust Homo sapiens ENCSR000BLO MA0062.3
GABPA SK-N-SH (neuroblastoma) Permissive Robust Homo sapiens ENCSR000BTG MA0062.3
GABPA HL-60 (acute myeloid leukemia) Permissive Robust Homo sapiens ENCSR000BTK MA0062.3
GABPA MCF7 (Invasive ductal breast carcinoma) Permissive Robust Homo sapiens ENCSR000BUK MA0062.3
GABPA MCF7 (Invasive ductal breast carcinoma) Permissive Robust Homo sapiens ENCSR038RXU MA0062.3
GABPA K562 (myelogenous leukemia) Permissive Robust Homo sapiens ENCSR290MUH MA0062.3
GABPA GM12878 (female B-cells lymphoblastoid cell line) Permissive Robust Homo sapiens ENCSR331HPA MA0062.3
GABPA CD34+CD133+ hematopoietic progenitors Permissive Robust Homo sapiens GSE24933 ... MA0062.3
GABPA MEL cell line Permissive Mus musculus ENCSR000ESK ... MA0062.3
GABPA CH12.LX (Mouse lymphoma) Permissive Robust Mus musculus ENCSR000EQS ... MA0062.3
GABPA CD4+ T-cells Permissive Robust Mus musculus GSE101936 ... MA0062.3
GABPA liver Permissive Robust Homo sapiens ENCSR350ORK MA0062.3
GABPA HepG2 (hepatoblastoma) Permissive Robust Homo sapiens ENCSR269TNX MA0062.3
GABPA GM12878 (female B-cells lymphoblastoid cell line) Permissive Robust Homo sapiens GSE53366 ... MA0062.3
GABPA GM12878 (female B-cells lymphoblastoid cell line) Permissive Robust Homo sapiens GSE53366 ... MA0062.3
GABPA RWPE1 (prostate epithelial cells) Permissive Homo sapiens GSE29808 MA0062.3
GABPA HeLa (cervical adenocarcinoma) Permissive Robust Homo sapiens GSE31417 MA0062.3
GABPA Jurkat (T-cells) Permissive Robust Homo sapiens GSE49091 MA0062.3
GABPA DU145 (prostate carcinoma) Permissive Robust Homo sapiens GSE59021 MA0062.3
GABPA HepG2 (hepatoblastoma) Permissive Robust Homo sapiens GSE72082 MA0062.3
GABPA VCaP (prostate carcinoma) ETOH Permissive Robust Homo sapiens GSE49091 MA0062.3
GABPA VCaP (prostate carcinoma) R1881 Permissive Robust Homo sapiens GSE49091 MA0062.3
GABPA VCaP (prostate carcinoma) Permissive Robust Homo sapiens GSE49091 MA0062.3